410 related articles for article (PubMed ID: 7909479)
21. Genetic correction of cultured T cells from an adenosine deaminase-deficient patient: characteristics of non-transduced and transduced T cells.
Braakman E; Van Beusechem VW; Van Krimpen BA; Fischer A; Bolhuis RL; Valerio D
Eur J Immunol; 1992 Jan; 22(1):63-9. PubMed ID: 1730260
[TBL] [Abstract][Full Text] [Related]
22. [The gene therapy for a patient with ADA deficiency; report of the first gene therapy trial in Japan].
Ariga T; Kawamura N; Sakiyama Y
Nihon Rinsho; 1997 Jun; 55(6):1572-9. PubMed ID: 9200950
[TBL] [Abstract][Full Text] [Related]
23. The hematopoietic stromal microenvironment promotes retrovirus-mediated gene transfer into hematopoietic stem cells.
Chertkov JL; Jiang S; Lutton JD; Harrison J; Levere RD; Tiefenthaler M; Abraham NG
Stem Cells; 1993 May; 11(3):218-27. PubMed ID: 8318909
[TBL] [Abstract][Full Text] [Related]
24. Gene transfer of adenosine deaminase into primitive human hematopoietic progenitor cells.
Cournoyer D; Scarpa M; Mitani K; Moore KA; Markowitz D; Bank A; Belmont JW; Caskey CT
Hum Gene Ther; 1991; 2(3):203-13. PubMed ID: 1751590
[TBL] [Abstract][Full Text] [Related]
25. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
Ramsey WJ; Mullen CA; Blaese RM
Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
[TBL] [Abstract][Full Text] [Related]
26. Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation.
Blackburn MR; Kellems RE
Adv Immunol; 2005; 86():1-41. PubMed ID: 15705418
[TBL] [Abstract][Full Text] [Related]
27. Severe combined immunodeficiency of reduced severity due to homozygosity for an adenosine deaminase missense mutation (Arg253Pro).
Hirschhorn R; Yang DR; Insel RA; Ballow M
Cell Immunol; 1993 Dec; 152(2):383-93. PubMed ID: 8258146
[TBL] [Abstract][Full Text] [Related]
28. Hyperbilirubinemia and rapid fatal hepatic failure in severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID).
Kühl JS; Schwarz K; Münch A; Schmugge M; Pekrun A; Meisel C; Wahn V; Ebell W; von Bernuth H
Klin Padiatr; 2011 Mar; 223(2):85-9. PubMed ID: 21271505
[TBL] [Abstract][Full Text] [Related]
29. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
Blaese RM
Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
[TBL] [Abstract][Full Text] [Related]
30. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
31. Management options: SCIDS with adenosine deaminase deficiency.
Hilman BC; Sorensen RU
Ann Allergy; 1994 May; 72(5):395-403; quiz 403-4, 407. PubMed ID: 8179225
[TBL] [Abstract][Full Text] [Related]
32. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
Silver JN; Flotte TR
Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
[TBL] [Abstract][Full Text] [Related]
33. Generation of normal lymphocyte populations following transplantation of adenosine-deaminase-deficient fetal liver cells.
Migchielsen AA; Knaän-Schanzer S; Breuer ML; Hershfield MS; Valerio D
Bone Marrow Transplant; 1997 Jun; 19(11):1137-43. PubMed ID: 9193758
[TBL] [Abstract][Full Text] [Related]
34. In vivo methotrexate selection of murine hemopoietic cells transduced with a retroviral vector for Gaucher disease.
Havenga M; Valerio D; Hoogerbrugge P; Es H
Gene Ther; 1999 Oct; 6(10):1661-9. PubMed ID: 10516714
[TBL] [Abstract][Full Text] [Related]
35. Visible integration of the adenosine deaminase (ADA) gene into the recipient genome after gene therapy.
Egashira M; Ariga T; Kawamura N; Miyoshi O; Niikawa N; Sakiyama Y
Am J Med Genet; 1998 Jan; 75(3):314-7. PubMed ID: 9475605
[TBL] [Abstract][Full Text] [Related]
36. [Gene therapy for adenosine deaminase (ADA) deficiency: review of the past, the present and the future].
Ariga T
Nihon Rinsho; 2001 Jan; 59(1):72-5. PubMed ID: 11197865
[TBL] [Abstract][Full Text] [Related]
37. Autologous transplantation of retrovirally transduced bone marrow or neonatal blood cells into cats can lead to long-term engraftment in the absence of myeloablation.
Simonaro CM; Haskins ME; Abkowitz JL; Brooks DA; Hopwood JJ; Zhang J; Schuchman EH
Gene Ther; 1999 Jan; 6(1):107-13. PubMed ID: 10341882
[TBL] [Abstract][Full Text] [Related]
38. Long-term expression of human adenosine deaminase in mice after transplantation of bone marrow infected with amphotropic retroviral vectors.
Osborne WR; Hock RA; Kaleko M; Miller AD
Hum Gene Ther; 1990; 1(1):31-41. PubMed ID: 2081183
[TBL] [Abstract][Full Text] [Related]
39. Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells.
van Beusechem VW; Kukler A; Heidt PJ; Valerio D
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7640-4. PubMed ID: 1502175
[TBL] [Abstract][Full Text] [Related]
40. A murine model for genetic manipulation of the T cell compartment.
Gu J; Kuo ML; Rivera A; Sutkowski N; Ron Y; Dougherty JP
Exp Hematol; 1996 Oct; 24(12):1432-40. PubMed ID: 8913290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
